Literature DB >> 26253786

Pancreatic β-Cells Limit Autoimmune Diabetes via an Immunoregulatory Antimicrobial Peptide Expressed under the Influence of the Gut Microbiota.

Jia Sun1, Laetitia Furio2, Ramine Mecheri3, Anne M van der Does4, Erik Lundeberg4, Loredana Saveanu5, Yongquan Chen1, Peter van Endert5, Birgitta Agerberth6, Julien Diana7.   

Abstract

Antimicrobial peptides (AMPs) expressed by epithelial and immune cells are largely described for the defense against invading microorganisms. Recently, their immunomodulatory functions have been highlighted in various contexts. However how AMPs expressed by non-immune cells might influence autoimmune responses in peripheral tissues, such as the pancreas, is unknown. Here, we found that insulin-secreting β-cells produced the cathelicidin related antimicrobial peptide (CRAMP) and that this production was defective in non-obese diabetic (NOD) mice. CRAMP administrated to prediabetic NOD mice induced regulatory immune cells in the pancreatic islets, dampening the incidence of autoimmune diabetes. Additional investigation revealed that the production of CRAMP by β-cells was controlled by short-chain fatty acids produced by the gut microbiota. Accordingly, gut microbiota manipulations in NOD mice modulated CRAMP production and inflammation in the pancreatic islets, revealing that the gut microbiota directly shape the pancreatic immune environment and autoimmune diabetes development.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26253786     DOI: 10.1016/j.immuni.2015.07.013

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  106 in total

1.  Accounting for reciprocal host-microbiome interactions in experimental science.

Authors:  Thaddeus S Stappenbeck; Herbert W Virgin
Journal:  Nature       Date:  2016-06-09       Impact factor: 49.962

Review 2.  Impact of gut microbiota on gut-distal autoimmunity: a focus on T cells.

Authors:  Maran L Sprouse; Nicholas A Bates; Krysta M Felix; Hsin-Jung Joyce Wu
Journal:  Immunology       Date:  2019-01-21       Impact factor: 7.397

3.  Free fatty acid receptor 3 differentially contributes to β-cell compensation under high-fat diet and streptozotocin stress.

Authors:  Medha Priyadarshini; Connor Cole; Gautham Oroskar; Anton E Ludvik; Barton Wicksteed; Congcong He; Brian T Layden
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2020-02-19       Impact factor: 3.619

Review 4.  The crucial role of early-life gut microbiota in the development of type 1 diabetes.

Authors:  He Zhou; Lin Sun; Siwen Zhang; Xue Zhao; Xiaokun Gang; Guixia Wang
Journal:  Acta Diabetol       Date:  2020-07-25       Impact factor: 4.280

Review 5.  Role of Short Chain Fatty Acid Receptors in Intestinal Physiology and Pathophysiology.

Authors:  Medha Priyadarshini; Kumar U Kotlo; Pradeep K Dudeja; Brian T Layden
Journal:  Compr Physiol       Date:  2018-06-18       Impact factor: 9.090

6.  Modulation of the immune system by the gut microbiota in the development of type 1 diabetes.

Authors:  James A Pearson; Andrew Agriantonis; F Susan Wong; Li Wen
Journal:  Hum Vaccin Immunother       Date:  2018-09-19       Impact factor: 3.452

7.  Genistein ameliorates inflammation and insulin resistance through mediation of gut microbiota composition in type 2 diabetic mice.

Authors:  Rui Yang; Qiang Jia; Shomaila Mehmood; Shanfeng Ma; Xiaofen Liu
Journal:  Eur J Nutr       Date:  2020-10-17       Impact factor: 5.614

Review 8.  Tissue Tregs.

Authors:  Marisella Panduro; Christophe Benoist; Diane Mathis
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

Review 9.  Metagenome-wide association studies: fine-mining the microbiome.

Authors:  Jun Wang; Huijue Jia
Journal:  Nat Rev Microbiol       Date:  2016-07-11       Impact factor: 60.633

Review 10.  Novel perspectives on therapeutic modulation of the gut microbiota.

Authors:  Justin L McCarville; Alberto Caminero; Elena F Verdu
Journal:  Therap Adv Gastroenterol       Date:  2016-04-04       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.